Company

Sosei Group Corp

Headquarters: Tokyo, Japan

Employees: 198

CEO: Mr. Shinichi Tamura

JPX: 4565 +1.52%

Market Cap

¥143.83 Billion

JPY as of July 1, 2024

US$890.8 Million

Market Cap History

Sosei Group Corp market capitalization over time

Evolution of Sosei Group Corp market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Sosei Group Corp

Detailed Description

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Sosei Group Corp has the following listings and related stock indices.


Stock: JPX: 4565 wb_incandescent

Stock: FSX: JSS wb_incandescent

Details

Headquarters:

PMO Hanzomon

11th Floor 2-1 Kojimachi Chiyoda-ku

Tokyo, 102-0083

Japan

Phone: 81 3 5210 3290

Fax: 81 3 5210 3291